Recent Press Releases

Merck KGaA Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer

DARMSTADT, Germany, Sept. 12, 2014 /CNW/ - Merck KGaA, Darmstadt, Germany, announced today that its biopharmaceutical division will discontinue the clinical development program of its...

FDA Approves Use of Menactra® Vaccine for Booster Immunization Against Potentially Deadly Disease

HEADLINE2Approval aligns with Centers for Disease Control and Prevention's recommendations for meningococcal vaccination SWIFTWATER, Pa., Sept. 8, 2014 /PRNewswire-USNewswire/ -- Sanofi...

Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients

New breast cancer vaccine candidate, (GP2), provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is...

Soligenix Announces Issuance of US Patent for ThermoVax™ Technology

New patent includes composition of matter claims PRINCETON, N.J., Sept. 9, 2014 /PRNewswire/ -- Soligenix, Inc. (otcqb:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company...

PharmAthene Awarded Contract Of Up To $28.1 Million To Develop Next Generation Thermostable Anthrax Vaccine

ANNAPOLIS, Md., Sept. 10, 2014 /PRNewswire/ -- PharmAthene, Inc. (nyse mkt:PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that...

FDA Gives NewLink Genetics Approval to Proceed to Phase 1 Clinical Studies of Their Ebola Vaccine

AMES, IA -- (Marketwired) -- 09/04/14 -- NewLink Genetics Corporation (NASDAQ: NLNK) today announced that the United States Food and Drug Administration (FDA) has given permission for the Company to...

Johnson & Johnson Responds to Ebola Crisis with Commitment to Accelerate Vaccine Program in Collaboration with the US National Institutes of Health (NIH) and Provide Humanitarian Relief Aid

NEW BRUNSWICK, NJ, September 4, 2014 – Johnson & Johnson today announced it will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly...

New Analysis of Old HIV Vaccines Finds Potentially Protective Immune Response

Newswise — DURHAM, N.C. – Applying the benefit of hindsight, researchers at Duke Medicine have reanalyzed the findings of two historic pediatric HIV vaccine trials with encouraging...

Specialty Vaccine Company PaxVax Appoints Mark Meltz Executive Vice President and Chief Legal Officer

REDWOOD CITY, Calif., Sep 03, 2014 (BUSINESS WIRE) -- PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Mark Meltz as Executive Vice...

SANOFI PASTEUR'S DENGUE VACCINE CANDIDATE SUCCESSFULLY COMPLETES FINAL LANDMARK PHASE III CLINICAL EFFICACY STUDY IN LATIN AMERICA

- Second, large-scale phase III study successfully meets primary endpoint with overall vaccine efficacy of 60.8 percent and shows efficacy against each of the four dengue serotypes - - Additional...

Amgen Submits Marketing Authorization Application For Talimogene Laherparepvec To The European Medicines Agency

First Marketing Authorization Application for an Oncolytic Immunotherapy in the European Union THOUSAND OAKS, Calif., Sept. 2, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission...

Pfizer's Investigational Vaccine Candidate for Clostridium difficile Receives U.S. Food and Drug Administration Fast Track Designation

Thursday, August 28, 2014 - 8:00am EDT Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company's...

Polio: mutated virus breaches vaccine protection

Thanks to effective vaccination, polio is considered nearly eradicated. Each year only a few hundred people are stricken worldwide. However, scientists of the University of Bonn, together with...

OncoPep Raises $6.9 Million Series B Financing to Advance Novel Cancer Vaccines and Expands Phase 1/2a Clinical Trial

OncoPep Inc. today announced the closing of $6.9 million in Series B financing from new and existing investors. The financing included participation from angel groups family foundations and...

MVI Vaccine to Be Used in Clinical Trial of a New Combination Approach to Immunotherapy Funded by the Prostate Cancer Foundation and the Movember Foundation

HEADLINE2--Trial Pairs MVI-816 with a PD-1 Pathway Inhibitor to Treat Metastatic Prostate Cancer----Prostate Cancer Foundation/Movember Foundation Award Goes to the University of Wisconsin to...

Biothera Awarded NIH Grant for Fungal Vaccine Development

HEADLINE2Funds to Support Ongoing Research with California Institute for Medical Research EAGAN, Minn., Aug 27, 2014 (BUSINESS WIRE) -- The National Institutes of Health has awarded a small...

Ebola vaccine trials fast-tracked by international consortium

A candidate Ebola vaccine could be given to healthy volunteers in the UK, The Gambia and Mali as early as September, as part of an series of safety trials of potential vaccines aimed at preventing...

Ebola Vaccine Using Immunovaccine's DepoVax Proves Highly Efficacious in Non-Human Primate Study

Halifax, Nova Scotia; August 25, 2014 – Immunovaccine Inc. ("Immunovaccine") (TSX-V: IMV), a clinical stage vaccine company, today announced positive results for a vaccine formulated...

Study with Diamyd Medical's diabetes vaccine awarded EU-funding

Diamyd Medical (NASDAQ OMX First North, Ticker: DMYD B) informs that the ongoing combination study DIABGAD has been awarded EUR 120 000, corresponding to about SEK 1.1 million, in EU-funding. The...

Vaccinogen Completes Initial Closing of an $80 Million Financing

FREDERICK, Md., Aug. 25, 2014 /PRNewswire/ -- Vaccinogen, Inc., (OTC.QB: VGEN) a cancer immunotherapy development company, announced today that it completed the initial closing of a private...